AMC 303

Drug Profile

AMC 303

Alternative Names: AMC-303

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator amcure
  • Class Antineoplastics; Peptides
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the the American Association for Cancer Research Annual Meeting 2017 (AACR-2017)
  • 27 Oct 2016 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in Belgium, Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top